Full Press Release Details
Zura Bio to Participate
in the Cantor Fitzgerald Global Healthcare Conference
- (BUSINESS WIRE) - August 20, 2025 - Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"),
a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with
unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare
Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor meetings
of the presentation will be available in the Investors section of the Company's website under News & Events. A replay
will remain archived for at least 30 days.
Zura Bio is a clinical-stage,
multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs. The
Company's pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with
the goal of improving efficacy, safety, and dosing convenience for patients.
lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies in adults, including
TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. Additional product candidates, crebankitug (ZB-168) and
torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and
inflammatory conditions.
For more information,
please visit www.zurabio.com.